Comparative analysis between the HER2 status in primary breast cancer tissue and the detection of isolated tumor cells in the bone marrow

Breast Cancer Research and Treatment
C SchindlbeckK Friese

Abstract

The presence of isolated tumor cells in the bone marrow (ITC-BM) of breast cancer patients is an independent prognostic parameter, indicating hematogenous tumor cell dissemination. While the HER2 status of breast cancer tissue has predictive value for the efficacy of different therapies, its prognostic relevance is controversial. To investigate the relationship between HER2 and ITC-BM, we retrospectively analyzed tumor tissues of 327 patients who underwent bone marrow aspiration at primary diagnosis or during the disease-free interval. Screening for ITC-BM was performed immunocytochemically, using the anti-cytokeratin antibody A45 B/B3. HER2 was determined by immunohistochemistry (IHC) with the antibody CB 11 (n = 277) and by fluorescence in situ hybridization (FISH, PathVision, Vysis, n = 206). ITC-BM were found in 83 of 327 patients (25.4%), with a median of 2.0 per 2 x 10(6 ) mononuclear cells. HER2 positivity (2+ /3+ ) was demonstrated in 18.8% of the tumors, amplification by FISH in 56 of 206 cases (27.2%). Established pathological parameters,tiviathological parameters, such as tumor size (p = 0.15), lymph node status (p = 0.93) and HER2 did not predict the presence of ITC-BM. After a median follow-up of 49 months (1-255),...Continue Reading

References

Sep 1, 1993·Journal of the National Cancer Institute·K PantelG Riethmüller
Jul 16, 1997·Journal of the National Cancer Institute·S B FoxA L Harris
Jan 7, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·S BraunK Pantel
Oct 31, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·G PaulettiD J Slamon
Feb 15, 2001·International Journal of Cancer. Journal International Du Cancer·I ZvibelM Papa
Feb 22, 2001·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·B GerberK Friese
Feb 24, 2001·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·A LebeauU Löhrs
Aug 16, 2001·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·G GebauerW Jäger
Aug 28, 2001·Annals of Oncology : Official Journal of the European Society for Medical Oncology·T CookeP Stanton
Nov 6, 2001·Oncology·W Hanna
Dec 18, 2001·The Journal of Pathology·J M BartlettT G Cooke
Feb 1, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Charles L VogelMichael Press
Mar 20, 2002·Clinical Breast Cancer·K Pantel, S Braun
Mar 29, 2002·Journal of Surgical Oncology·Shinichi TsutsuiShinya Oda
Apr 12, 2002·International Journal of Cancer. Journal International Du Cancer·Gilbert SpizzoGünther Gastl
Apr 30, 2002·Strahlentherapie und Onkologie : Organ der Deutschen Röntgengesellschaft ... [et al]·U R Kleeberg
Jun 6, 2002·Journal of the National Cancer Institute·Patrick C RocheEdith A Perez
Jul 18, 2002·Endocrine-related Cancer·M Harries, I Smith
Nov 8, 2002·Oncology·Angelo Di LeoFrédérique Penault-Llorca
Mar 14, 2003·The Journal of Pathology·John BartlettTim Cooke
Mar 22, 2003·Experimental Cell Research·Thomas HolbroNancy E Hynes
May 20, 2003·APMIS : Acta Pathologica, Microbiologica, Et Immunologica Scandinavica·Torill SauerRolf Karesen
Sep 16, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·G WiedswangB Naume
Aug 27, 2005·The New England Journal of Medicine·Stephan BraunKlaus Pantel

❮ Previous
Next ❯

Citations

Mar 18, 2005·Journal of Translational Medicine·Ute WoelfleKlaus Pantel
Jan 22, 2005·Current Opinion in Genetics & Development·Erik Sahai

❮ Previous
Next ❯

Related Concepts

Related Feeds

Breast Cancer: Chemo-Resistance

Some cancers are difficult to treat and aggressive including the "triple-negative" breast cancer. This type of cancer is chemoresistant even before chemotherapy begins. Here are the latest discoveries chemo-resistance in breast cancer.